Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALN-HBV
- Development stage
- Discontinued
- Lead developer
- Vir Biotechnology
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Subcutaneous
01
Overview
ALN-HBV is an investigational RNA interference (RNAi) therapeutic designed for the treatment of chronic hepatitis B virus (HBV) infection. It is a GalNAc-conjugated small interfering RNA (siRNA) that targets highly conserved sequences in the HBV genome, specifically within the X open reading frame. By silencing all major HBV transcripts, ALN-HBV aims to reduce production of hepatitis B surface antigen (HBsAg), thereby restoring host immune response and potentially achieving a functional cure for chronic HBV patients. Preclinical studies have demonstrated potent and durable knockdown of HBsAg in rodent models, with effects lasting up to four months after multiple doses. The drug is administered subcutaneously and has shown good tolerability in animal toxicology studies[1][3][4][5][8].
02
Targets
HBV X RNA (Hepatitis B virus X region RNA transcript)HBx (Hepatitis B virus X protein)HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on ALN-HBV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALN-HBV.